European Commission Approves Dostarlimab Plus Chemo for All Advanced/Recurrent Endometrial Cancer
Frontline dostarlimab plus chemotherapy has been approved in the EU for all adult patients with primary advanced or recurrent endometrial cancer.
Related Articles
PER® International Symposium on Melanoma and Other Cutaneous Malignancies
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Health Canada Green Lights Fruquintinib for Metastatic Colorectal Cancer
Health Canada approved fruquintinib for select patients with metastatic colorectal cancer.
OncLive – Clinical Oncology News, Cancer Expert Insights
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
OncLive – Clinical Oncology News, Cancer Expert Insights
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Adjuvant Multi-Agent Chemotherapy Extends OS in Pancreatic Cancer – Oncology Nurse Advisor
Single-agent adjuvant chemotherapy did not improve overall survival when compared to no adjuvant chemotherapy.
FDA Grants Breakthrough Device Designation to DCISionRT for Breast Cancer With DCIS
The FDA has granted a breakthrough device designation to the DCISionRT test for patients with breast cancer with ductal carcinoma in situ.
OncLive – Clinical Oncology News, Cancer Expert Insights
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Collection Details : Oncology Times
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
Clinical Perspectives: Utilizing CAR-T Therapy in R/R MM
Panelists discuss how emerging data on chimeric antigen receptor T-cell therapies ciltacabtagene autoleucel and idecabtagene vicleucel for earlier treatment lines in relapsed/refractory multiple myeloma influence…
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
